H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data

Core Insights - Assembly Biosciences, Inc. (NASDAQ:ASMB) is highlighted as a top long-term biotechnology stock to consider for investment [1] - H.C. Wainwright has reaffirmed a Buy rating and a price target of $50 for Assembly Biosciences following promising interim data for ABI-5366, an oral treatment for recurrent genital herpes [2] Company Overview - Assembly Biosciences focuses on developing and commercializing small-molecule therapies for serious viral diseases, particularly chronic hepatitis B virus (HBV) and herpesviruses [2] Clinical Development - The interim data presented for ABI-5366 demonstrated strong antiviral activity, favorable tolerability, and a dosing profile that supports weekly or monthly administration [2] - These results are seen as a validation of Assembly's helicase-primase inhibitor platform, reducing the risk associated with advancing ABI-5366 into Phase 2 trials [2] - The company plans to initiate Phase 2 clinical studies by mid-2026, indicating ongoing progress in its antiviral pipeline [2]